Transient therapy-related surge in serum tumor biomarkers: Characterizing behavior and postulating its biologic role

Critical Reviews in Oncology/Hematology

Volumn 86, Issue 1, 2013, Pages 15-22

  Mundle, Suneel D ^a,c   Marathe, Anuj S ^b   Chelladurai, Mohan ^a  

^a Janssen Services LLC   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c ILLINOIS MATHEMATICS AND SCIENCE ACADEMY   (United States)

Author keywords

Biomarker flare; Cancer; Therapy related surge; Tumor biomarkers

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CASPASE 3; CHORIONIC GONADOTROPIN; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMMUNOGLOBULIN M; INHIBITOR OF APOPTOSIS PROTEIN 2; INTERLEUKIN 2; NEURON SPECIFIC ENOLASE; OXALIPLATIN; PROSTATE SPECIFIC ANTIGEN; RITUXIMAB; TOPOTECAN; TUMOR MARKER;

APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER REGRESSION; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COLORECTAL CARCINOMA; GASTROINTESTINAL TUMOR; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; OVARY CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SERUM TUMOR BIOMARKER SURGE; STOMACH CANCER; TREATMENT RESPONSE; VISCERAL METASTASIS; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC PROTOCOLS; DATA INTERPRETATION, STATISTICAL; HUMANS; MALE; NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84875053034     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.09.006     Document Type: Review

References (45)

1. Conley B.A., Taube S.E. Prognostic and predictive markers in cancer. Disease Markers 2004, 20:35-43.
2. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nature Reviews Cancer 2005, 5:845-856.
3. Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 2001, 69:89-95. Biomarker Definitions Working Group.
4. Rhea J.M., Molinaro R.J. Cancer biomarkers: surviving the journey from bench to bedside 2011 March, Medical Laboratory Observer, www.mlo-online.com. p. 10-18.
5. Floyd E., McShane T. Development and use of biomarkers in oncology drug development. Toxicologic Pathology 2004, 32(Suppl. 1):106-114.
6. FDA Medical Device Website. Overview of IVD regulation. [accessed on 13.01.12]. http://www.fda.gov/medicaldevices/deviceregulationandguidance/ivdregulationassistance/p3.
7. Sørbye H., Dahl O. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncologica 2004, 43:495-498.
8. Ailawadhi S., Sunga A., Rajput A., Yang G.Y., Smith J., Fakih M. Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology 2006, 70:49-53.
9. An X., Ding P.R., Li Y.H., et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010, 15:516-522.
10. Strimpakos A.S., Cunningham D., Mikropoulos C., Petkar I., Barbachano Y., Chau I. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Annals of Oncology 2010, 21:1013-1019.
11. Kim H.J., Lee K.W., Kim Y.J., et al. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer. Acta Oncologica 2009, 48:385-390.
12. Olbert P.J., Hegele A., Kraeuter P., Heidenreich A., Hofmann R., Schrader A.J. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anti-Cancer Drugs 2006, 17:993-996.
13. Fosså S.D., Vaage S., Letocha H., et al. Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC) - delayed response and flare phenomenon should be considered. Scandinavian Journal of Urology and Nephrology 2002, 36:34-39. Norwegian Urological Cancer Group.
14. Heidenreich A., Sommer F., Ohlmann C.H., et al. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Cancer 2004, 101:948-956.
15. Nelius T., Klatte T., de Riese W., Filleur S. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy. International Urology and Nephrology 2008, 40:97-104.
16. Sella A., Sternberg C.N., Skoneczna I., Kovel S. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU International 2008, 102:1607-1609.
17. Thuret R., Massard C., Gross-Goupil M., et al. The postchemotherapy PSA surge syndrome. Annals of Oncology 2008, 19:1308-1311.
18. de Wit R., Collette L., Sylvester R., et al. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. British Journal of Cancer 1998, 78:1350-1355.
19. Vogelzang N.J., Lange P.H., Goldman A., Vessela R.H., Fraley E.E., Kennedy B.J. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Research 1982, 42:4855-4861.
20. Horwich A., Peckham M.J. Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. Cancer Treatment Reports 1986, 70:1329-1331.
21. Kim H.S., Yom C.K., Kim H.J., et al. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy. Breast Cancer Research and Treatment 2010, 121:777-788.
22. Wu S.C., Chou F.F., Rau K.M. Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Research and Treatment 2010, 124:879-882.
23. Hayes D.F., Kiang D.T., Korzun A.H., Tondini C., Wood W.C., Kufe D.W. CA 15-3 and CEA spikes during chemotherapy for metastatic breast cancer. Proceedings of the Annual Meeting - American Society of Clinical Oncology 1988, 7:38. (abstr, 146).
24. Kiang D.T., Greenberg L.J., Kennedy B.J. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990, 65:193-199.
25. Bork E., Hansen M., Urdal P., et al. Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide. European Journal of Cancer and Clinical Oncology 1988, 24:1033-1038.
26. Fischbach W., Schwarz-Wallrauch C., Jany B. Neuron-specific enolase and thymidine kinase as an aid to the diagnosis and treatment monitoring of small cell lung cancer. Cancer 1989, 63:1143-1149.
27. Waalkes T.P., Abeloff M.D., Woo K.B., Ettinger D.S., Ruddon R.W., Aldenderfer P. Carcinoembryonic antigen for monitoring patients with small cell carcinoma of the lung during treatment. Cancer Research 1980, 40:4420-4427.
28. Hotta K., Kiura K., Tabata M., et al. Role of early serial change in serum carcinoembryonic antigen levels as a predictive marker for radiological response to gefitinib in Japanese patients with non-small cell lung cancer. Anticancer Research 2007, 27:1737-1742.
29. Leleu X., Xie W., Bagshaw M. The role of serum immunoglobulin free light chain in response and progression in Waldenstrom Macroglobulinemia. Clinical Cancer Research 2011, 17:3013-3018.
30. Ghobrial I.M., Fonseca R., Griepp P.R., et al. Initial immunoglobulin 'M' flare after rituximab therapy in patients diagnosed with Waldenstrom Macroglobulinemia. Cancer 2004, 101:2593-2598.
31. Coleman R.L., Gordon A., Barter J., Sun S., Rackoff W., Herzog T.J. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. The Oncologist 2007, 12:72-78.
32. Gilligan T.D., Seidenfeld J., Basch E.M., et al. American Society of Clinical Oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. Journal of Clinical Oncology 2010, 28:3388-3404.
33. Olofsson S.-E., Tandstad T., Jerkeman M., et al. Population-based treatment guided by tumor marker decline in patients with nonseminomatous germ cell tumor: a report from the Swedish-Norwegian testicular cancer. Journal of Clinical Oncology 2011, 29:2032-2039.
34. Locker G.Y., Hamilton S., Harris J., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. Journal of Clinical Oncology 2006, 24:5313-5327.
35. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology 2008, 26:1148-1159.
36. Taheri M., Saragovi H.U., Stanners C.P. The adhesion and differentiation-inhibitory activities of the immunoglobulin superfamily member, carcinoembryonic antigen, can be independently blocked. Journal of Biological Chemistry 2003, 278:14632-14639.
37. Li Y., Cao H., Jiao Z., et al. Carcinoembryonic antigen interacts with TGF-β receptor and inhibits TGF-β signaling in colorectal cancers. Cancer Research 2010, 70:8159-8168.
38. Modrak D.E., Gold D.V., Goldenberg D.M., Bloomenthal R.D. Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy. Tumour Biology 2003, 24:32-39.
39. Ohtsukasa S., Okabe S., Yamashita H., Iwai T., Sugihara K. Increased expression of CEA and MHC Class I in colorectal cancer cell lines exposed to chemotherapy drugs. Journal of Cancer Research and Clinical Oncology 2003, 129:719-726.
40. Correale P., Cusi M.G., Tsang K.Y., et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. Journal of Clinical Oncology 2005, 23:8950-8958.
41. Dudich E., Semenkova L., Dudich I., et al. Alpha-fetoprotein causes apoptosis in tumor cells via a pathway independent of CD95, TNFR1 and TNFR2 through activation of caspase-3-like proteases. European Journal of Biochemistry 1999, 266:750-761.
42. Semenkova L., Dudich E., Dudich I., et al. Alpha-fetoprotein positively regulates cytochrome c-mediated caspase activation and apoptosome complex formation. European Journal of Biochemistry 2003, 270:4388-4399.
43. Kaufmann S.H., Earnshaw W.C. Induction of apoptosis by cancer chemotherapy. Experimental Cell Research 2000, 256:42-49.
44. Wang P., Song J.H., Song D.K., Zhang J., Hao C. Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induced apoptosis. Cellular Signalling 2006, 18:1528-1535.
45. Yang X., Zhang Y., Zhang L., Zhang L., Mao J. Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Cancer Letters 2008, 271:281-293.